{"id":389000,"date":"2024-12-24T00:00:00","date_gmt":"2024-12-24T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0015-2024-biopharma-gastroesophageal-cancer-disease-landscape-forecast-g7-2024\/"},"modified":"2026-03-31T10:27:33","modified_gmt":"2026-03-31T10:27:33","slug":"dlsfon0015-2024-biopharma-gastroesophageal-cancer-disease-landscape-forecast-g7-2024","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0015-2024-biopharma-gastroesophageal-cancer-disease-landscape-forecast-g7-2024\/","title":{"rendered":"Gastroesophageal Cancer | Disease Landscape &#038; Forecast | G7 | 2024"},"content":{"rendered":"<p>The advent of Opdivo (Bristol Myers Squibb \/ Ono Pharmaceutical) and Keytruda (Merck &#038; Co.) has revolutionized the treatment of gastroesophageal cancer, leading to substantial growth of this indication\u2019s drug therapy market. The expected approval of novel immune checkpoint inhibitors will further reshape the HER2-negative gastroesophageal cancer therapy. Multimodal therapy consisting of HER2-targeted agents, immune checkpoint inhibitors, and chemotherapy has expanded therapeutic options for HER2-positive disease. We expect the gastroesophageal cancer therapy landscape to gain additional complexity as novel biomarker-specific therapies (claudin 18.2 inhibitors and FGFR2b inhibitors) expand the range of available treatments. Given the significant progress in the late-phase pipeline, we expect the approval of several new therapies for gastroesophageal cancer during the forecast period.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>How is gastroesophageal cancer segmented by subpopulation, and what is the size of the drug-treatable and drug-treated populations?<\/li>\n<li>What are the key current therapies for gastroesophageal cancer, and how are they positioned in the treatment algorithm?<\/li>\n<li>Which emerging therapies are the most promising, and how will they shape the future of the gastroesophageal cancer therapy market?<\/li>\n<li>What are the drivers of and constraints on the gastroesophageal cancer therapy market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Content highlights<\/strong><\/p>\n<p>Geographies: United States, EU5, Japan<\/p>\n<p>Primary research: 19 country-specific interviews with thought-leading medical oncologists, supported by survey data collected for this and other Clarivate research.<\/p>\n<p>Epidemiology: Diagnosed and recurrent incidence of gastroesophageal cancer by country, segmented by stage of disease, histology, HER2 status, and line of therapy<\/p>\n<p>Forecast: 10-year, annualized, drug-level sales and patient share of key gastroesophageal cancer therapies through 2033, segmented by brands \/ generics \/ biosimilars and drug-treatable populations<\/p>\n<p>Drug treatments: Coverage of key current and emerging therapies<\/p>\n<p>\u00a0<\/p>\n<p><strong>Product description <\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Key features<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.<\/p>\n<p>Disease Landscape &#038; Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-389000","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-esophageal-cancer","biopharma-therapy-areas-gastric-cancer","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389000","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389000\/revisions"}],"predecessor-version":[{"id":575848,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389000\/revisions\/575848"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389000"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}